Bringing the Oncology Community Together
Promising Findings for Afatinib–Cetuximab Combo in Previously Treated EGFR-Mutant Lung Cancer
Results of an early-phase study have shown the combination of afatinib (Gilotrif) and cetuximab (Erbitux) has utility in EGFR-mutant lung cancer patients who have developed resistance to gefitinib (Tarceva) and erlotinib (Iressa).
FDA Expands Ibrutinib's CLL Approval
The FDA has expanded the approval of ibrutinib to include the treatment of patients with chronic lymphocytic leukemia who have received at least one previous therapy and harbor a 17p deletion.
Sorafenib Does Not Improve PFS in Phase III Breast Cancer Study
A phase III trial analyzing sorafenib for the treatment of patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival.
FDA Approves Idelalisib for CLL, SLL, and FL
The FDA has approved idelalisib in combination with rituximab for patients with high-risk relapsed or refractory CLL and as a single-agent for two types of iNHL.
Extended Adjuvant Neratinib Improves DFS in Phase III Breast Cancer Study
Extended adjuvant treatment with neratinib (PB272, HKI-272) significantly extended improved disease-free survival (DFS) compared with placebo for patients with HER2-positive breast cancer who received prior adjuvant trastuzumab
Bevacizumab Receives Priority Review in Ovarian Cancer
The FDA has assigned a priority review designation to bevacizumab (Avastin) in combination with chemotherapy for patients with recurrent platinum-resistant ovarian cancer.
Immunotherapy Combination Receives Breakthrough Designation for Pancreatic Cancer
The combination of the immunotherapy CRS-207 and the vaccine GVAX Pancreas has received a breakthrough therapy designation from the FDA for its potential as a treatment for patients with metastatic pancreatic cancer.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.